Lilly: retatrutide beats Ozempic 2 mg on A1C reduction and weight loss in head-to-head trial
FROM THE WIRE · FINANCE.YAHOO.COM
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeks TRANSCEND-T2D-2 marks the sixth…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA positive Phase 3 head-to-head win over a benchmark drug strengthens the outlook for a key Lilly candidate in diabetes and obesity.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks.
- 02Participants lost an average of 44-47 lbs (20-21%) vs. 21 lbs (9%) with Ozempic 2 mg.
- 03TRANSCEND-T2D-2 is the sixth Phase 3 trial in which retatrutide has shown efficacy.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets